Dataset Information


Cytokine signatures in chronic fatigue syndrome patients: a Case Control Study and the effect of anakinra treatment.

ABSTRACT: BACKGROUND:Cytokine disturbances have been suggested to be associated with the Chronic Fatigue Syndrome/Myalgic encephalomyelitis (CFS/ME) for decades. METHODS:Fifty female CFS patients were included in a study on the effect of the interleukin-1-receptor antagonist anakinra or placebo during 4 weeks. EDTA plasma was collected from patients before and directly after treatment. At baseline, plasma samples were collected at the same time from 48 healthy, age-matched female neighborhood controls. A panel of 92 inflammatory markers was determined in parallel in 1 ?L samples using a 'proximity extension assay' (PEA) based immunoassay. Since Transforming growth factor beta (TGF-?) and interleukin-1 receptor antagonist (IL-1Ra) were not included in this platform, these cytokines were measured with ELISA. RESULTS:In CFS/ME patients, the 'normalized protein expression' value of IL-12p40 and CSF-1 was significantly higher (p value 0.0042 and 0.049, respectively). Furthermore, using LASSO regression, a combination of 47 markers yielded a prediction model with a corrected AUC of 0.73. After correction for multiple testing, anakinra had no effect on circulating cytokines. TGF-? did not differ between patients and controls. CONCLUSIONS:In conclusion, this study demonstrated increased IL-12p40 and CSF-1 concentrations in CFS/ME patients in addition to a set of predictive biomarkers. There was no effect of anakinra on circulating cytokines other than IL-1Ra. TRIAL REGISTRATION:ClinicalTrials.gov Identifier: NCT02108210 , Registered April 2014.


PROVIDER: S-EPMC5747240 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2010-01-01 | S-EPMC2887614 | BioStudies
2013-01-01 | S-EPMC4167802 | BioStudies
1000-01-01 | S-EPMC5576836 | BioStudies
2015-01-01 | S-EPMC4595002 | BioStudies
2009-01-01 | S-EPMC2732140 | BioStudies
2013-01-01 | S-EPMC3842096 | BioStudies
2018-01-01 | S-EPMC6232613 | BioStudies
2017-01-01 | S-EPMC5489802 | BioStudies
2016-01-01 | S-EPMC5342798 | BioStudies
2013-01-01 | S-EPMC3876332 | BioStudies